SCHEDULE: AQR Capital Management Adjusts Haemonetics Stake

AQR Capital Management, LLC and AQR Capital Management Holdings, LLC have filed an amendment to their Schedule 13G, reporting beneficial ownership of Haemonetics Corp. common stock.

Summary

• AQR Capital Management, LLC and AQR Capital Management Holdings, LLC have filed an amendment to their Schedule 13G for Haemonetics Corp.
• The filing indicates a shared power to vote and dispose of 2,149,735 shares and 2,266,489 shares, respectively.
• The aggregate amount beneficially owned by each reporting person is 2,266,489 shares.
• This ownership represents 4.99% of the class of securities.
• Both entities are organized in the United States.
• The filing certifies that the securities were acquired and are held in the ordinary course of business and not for the purpose of influencing control of the issuer.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral filing, primarily reporting a change in beneficial ownership that remains below a significant threshold, indicating no immediate strong sentiment.

Positives

• The reporting entities maintain beneficial ownership below the 5% threshold, suggesting a passive investment approach.
• The filing is an amendment, indicating ongoing compliance with reporting requirements.

Negatives

• No specific financial performance data or strategic updates are provided in this ownership filing.

Risks

• While not explicitly stated as a risk in this filing, any significant shift in beneficial ownership by large institutional investors could potentially influence market perception or trading dynamics.

Future Outlook

This filing does not contain forward-looking statements or guidance regarding Haemonetics Corp.'s future performance. It solely reports on beneficial ownership.

Management Comments

• "By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under 240.14a-11."

Industry Context

StockSavvy.ai notes that Schedule 13G filings are common for institutional investors managing significant assets. AQR Capital Management is a well-known quantitative investment firm, and their filings typically reflect their systematic investment strategies. This filing indicates their continued, albeit passive, interest in Haemonetics Corp. within the broader healthcare technology sector.

Stakeholder Impact

• Shareholders: The filing confirms a significant institutional investor's holdings, which can be a positive signal of confidence, though the ownership level remains below a controlling stake.

Next Steps

• Continued monitoring of AQR Capital Management's beneficial ownership filings for Haemonetics Corp.

Key Dates

Keywords

Haemonetics Corp, Schedule 13G, Beneficial Ownership, AQR Capital Management, Institutional Investor, Securities Ownership